The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection
Authors' conclusion
Our observations indicate that serum TRAcP5b, measured at 6 months after a Dmab injection, is not a useful early marker for time-dependent increased accumulation of osteoclasts in humans and for identification of patients at risk for a higher rebound increase in bone resorption.
Study context
- Population
- Women with postmenopausal osteoporosis treated with denosumab for 1–10 years; serum taken 6 months after last injectionDmab for 4.0 ± 2.3 years (range 1–10)
- Participants
- 59 women
- Exposure
- Group 1 vs Group 2
- Group 1n = 38
- Group 2n = 21
- Outcome
- Relationship between duration of Dmab treatment and serum TRAcP5b (marker of osteoclast numbers)
- Follow-up
- 6.0 months ± 15 days after last Dmab injection
Main finding
As reported in the abstract
Serum TRAcP5b and TRAcP5b/CTX ratio vs duration of Dmab treatment · 6 months after last injection
- Duration of Dmab treatment not related to serum TRAcP5b or TRAcP5b/CTX ratio, in the whole cohort or in each group separately
Observational data: associations, not effects.
Further findings
Correlation of serum TRAcP5b with serum CTX
- Spearman correlation (rs), p < 0.001
- 0.619
Correlation of serum TRAcP5b with serum P1NP and BMD
- Not correlated with serum P1NP or BMD at any skeletal site
Original publication
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection. Osteoporos Int. Published 2 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →